IBCSG 68-23 TREAT

  •  Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA).

    • Study Chair
      Francois Clement Bidard

      Statistician
      EORTC Headquarters
      Avenue E. Mounierlaan 83/11
      Brussel 1200 Bruxelles
      België - Belgique

      Trial Coordinator
      Meredith Kissel

      Data Manager
      EORTC Headquarters
      Avenue E. Mounierlaan 83/11
      Brussel 1200 Bruxelles
      België - Belgique

      Monitoring
      ETOP IBCSG Partners Foundation
      Coordinating Center, Bern, Switzerland
      Phone: +41 31 511 94 00
      Fax: +41 31 511 94 01
      Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

      Targeted Accrual
      220

      Protocol Release Date 
      October 13, 2023

      Trial Activation Date 
      December 15, 2023

      First Patient In 
      February 23, 2024

    ETOP IBCSG Partners Foundation
    Effingerstrasse 33
    3008 Bern, Switzerland

    Contact
    Phone: +41 31 511 94 00
    E-mail: contact@etop.ibcsg.org

    Member Login